Neurocrine Biosciences Stock News

NBIX earnings call for the period ending December 31, 2021.

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million 26%, missing the consensus of

Neurocrine Biosciences Inc (NASDAQ: Full story available on Benzinga.com

Recording the biggest intraday gain since March 2021, Neurocrine Biosciences <> is trading sharply higher on above-average volume despite its lower-than-expected financials for…

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-Developed Oncology Drug Eli Lilly

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call Transcript

INGREZZA® (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA® (valbenazine) 2022 Net Product Sales Guidance of $1.25 - $1.35 Billion Expanded Pipeline Expected to Deliver Multiple Registrational and Phase 2 Study Data Readouts Over the Next Two Years SAN DIEGO , Feb.

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million 26%, missing the consensus of $

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ: COOP ) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million. • MISTRAS Group (NYSE: MG ) is estimated to report quarterly earnings at $1.06 per share on revenue of $11.33 billion. • IAA (NYSE: IAA ) is estimated to report quarterly earnings at $0.62 per share on revenue of $500.71 million. • Fortis (NYSE: FTS ) is estimated to report quarterly earnings at $0.71 per share on revenue of $2.31 billion. • Enbridge (NYSE: ENB ) is estimated to report quarterly earnings at $0.58 per share on revenue of $8.88 billion. • Millicom Intl Cellular (NASDAQ: TIGO ) is expected to report quarterly earnings at $0.32 per share on revenue of $1.70 billion. • CAE (NYSE: CAE ) is expected to report quarterly earnings at $0.19 per share on revenue of $918.24 million. • Neurocrine Biosciences (NASDAQ: NBIX ) is projected to report quarterly earnings at $0.52 per share on revenue of $316.79 million. • Genpact (NYSE: G ) is projected to report quarterly earnings at $0.46 per share on revenue of $911.92 million. • Apollo Global Management (NYSE: APO ) is likely to report quarterly earnings at $1.10 per share …

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q4 earnings results on Friday, February 11th, before market open.The consensus EPS Estimate is $0.88 (-3.3% Y/Y) and…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland February 8 , 202 2 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2021. Business highlights QUVIVIQ (daridorexant) 25 mg and 50 mg approved by the US Food and Drug Administration (FDA) for the treatment of adults with insomnia Marketing Authorization Application for daridorexant for the treatment of adults with insomnia under review with European Medicines Agency, Swissmedic, and Health Canada PIVLAZ (clazosentan) 150 mg approved in Japan for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage Commercial organizations established in key markets in Europe and scaled-up in US and Japan in preparation for first product launches Phase 3 study with selatogrel for the treatment of acute myocardial infarction initiated Results from CARE study with cenerimod for systemic lupus erythematosus inform the decision to advance to Phase 3 Results for MODIFY study with lucerastat for Fabry disease show potential effect on organ function to be further investigated in the ongoing open-label extension Phase 2 proof-of-concept study with SO1RA for binge eating disorder completed recruitment Ponesimod to treat relapsing forms of multiple sclerosis approved in US and EU, resulting in Idorsia receiving first income from the revenue-sharing agreement with Janssen Pharmaceuticals Financial highlights Maintained strong balance sheet by successfully securing a CHF 600 m convertible bond US GAAP operating expenses 2021 at CHF 648 million Non-GAAP operating expenses 2021 at CHF 612 million Guidance for 202 2 : Net revenue around CHF 145 million US GAAP operating expenses around CHF 975 million and non-GAAP operating expenses around CHF 920 million leading to US GAAP operating loss of around CHF 840 million and non-GAAP operating loss of around CHF 785 million unforeseen events excluded Profitability target : The company is committed to become profitable and expects to reach this goal in 2025 with sales above CHF 1 billion.

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.